Clinical Efficacy Study of Deer Placenta Extract in Treating Scanty Menstruation Due to Qi and Blood Deficiency

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2026000432

Enrollment

Unknown

Registered

2026-02-26

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Light menstrual flow

Interventions

Traditional Chinese Medicine Group:Oral Deer Placenta Extract

Western Medicine Group:Take Femotone

Joint Group:Take Fenmatong and deer placenta ointment orally at the same time.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Meets diagnostic criteria for hypomenorrhea with Traditional Chinese Medicine pattern identification of qi and blood deficiency; (2) Age 18–40 years; (3) Absence of severe cardiovascular or cerebrovascular diseases; (4) Signed informed consent form; (5) Able to maintain stable follow-up.

Exclusion criteria

Exclusion criteria: (1) Individuals who do not meet Western medical diagnostic criteria or Traditional Chinese Medicine (TCM) pattern differentiation standards; (2) Patients with concomitant primary diseases such as liver/kidney disorders, cardiovascular/cerebrovascular conditions, hematological disorders, diabetes, or psychiatric illnesses; (3) Patients with malignant tumors including endometrial cancer, ovarian cancer, or breast cancer; (4) Patients with allergic constitutions, such as those with a history of allergy to two or more drugs or foods; or those with known allergy to any component of this drug; (5) Patients unable to comply with treatment or attend follow-up visits; (6) Patients currently participating in other drug clinical trials; (7) Pregnant or lactating women; (8) Patients concurrently taking other medications for hypomenorrhea.

Design outcomes

Primary

Measure	Time frame
Menstrual bleeding chart;	—

Secondary

Measure	Time frame
Follicle stimulating hormone(FSH);Luteinizing hormone(LH);Follicle stimulating hormone(FSH)/Luteinizing hormone(LH);Anti-M ü llerian hormone;Antral follicle count;	—

Countries

China

Contacts

Public ContactXin Mingwei

Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University

13552866767@163.com13552866767

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026